The Current State of Critical Limb Ischemia: A Systematic Review
Chronic critical limb ischemia, marked by intractable lower extremity ischemic rest pain and tissue loss, is a highly morbid condition that leads to the loss of ambulation and decreased quality of life. It is associated with a high risk of limb loss and mortality and presents a significant economic...
Uloženo v:
| Vydáno v: | JAMA surgery Ročník 151; číslo 11; s. 1070 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.11.2016
|
| Témata: | |
| ISSN: | 2168-6262, 2168-6262 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Chronic critical limb ischemia, marked by intractable lower extremity ischemic rest pain and tissue loss, is a highly morbid condition that leads to the loss of ambulation and decreased quality of life. It is associated with a high risk of limb loss and mortality and presents a significant economic burden to society.
To review the current state of epidemiology, pathophysiology, diagnosis, and treatment of critical limb ischemia.
An extensive literature search of the subject matter was conducted on material published in English between 1980 and 2016; both landmark and recently published articles were evaluated. Articles were reviewed if they included the terms critical limb ischemia, ischemic rest pain, gangrene, or extremity ulcers.
Critical limb ischemia represents the end stage of peripheral arterial disease. Because peripheral arterial disease is most commonly caused by atherosclerosis, critical limb ischemia is heavily associated with smoking and diabetes. Revascularization is the cornerstone of therapy to prevent limb amputation, and both open vascular surgery and endovascular therapy play a key role in the treatment of patients with critical limb ischemia. However, few scientific data are available to identify the optimal revascularization strategy, which has led to a significant amount of variability and equipoise in the treatment of this condition. Medical therapy plays a significant role in optimizing coexistent cardiovascular risk factors and a limited role in improving limb outcomes in nonrevascularizable disease.
Understanding critical limb ischemia and its treatment strategies is important for providing the best care for affected patients. Currently, ongoing randomized clinical trials in North America and the United Kingdom aim to provide data to support the best management of these patients. |
|---|---|
| AbstractList | Chronic critical limb ischemia, marked by intractable lower extremity ischemic rest pain and tissue loss, is a highly morbid condition that leads to the loss of ambulation and decreased quality of life. It is associated with a high risk of limb loss and mortality and presents a significant economic burden to society.
To review the current state of epidemiology, pathophysiology, diagnosis, and treatment of critical limb ischemia.
An extensive literature search of the subject matter was conducted on material published in English between 1980 and 2016; both landmark and recently published articles were evaluated. Articles were reviewed if they included the terms critical limb ischemia, ischemic rest pain, gangrene, or extremity ulcers.
Critical limb ischemia represents the end stage of peripheral arterial disease. Because peripheral arterial disease is most commonly caused by atherosclerosis, critical limb ischemia is heavily associated with smoking and diabetes. Revascularization is the cornerstone of therapy to prevent limb amputation, and both open vascular surgery and endovascular therapy play a key role in the treatment of patients with critical limb ischemia. However, few scientific data are available to identify the optimal revascularization strategy, which has led to a significant amount of variability and equipoise in the treatment of this condition. Medical therapy plays a significant role in optimizing coexistent cardiovascular risk factors and a limited role in improving limb outcomes in nonrevascularizable disease.
Understanding critical limb ischemia and its treatment strategies is important for providing the best care for affected patients. Currently, ongoing randomized clinical trials in North America and the United Kingdom aim to provide data to support the best management of these patients. Chronic critical limb ischemia, marked by intractable lower extremity ischemic rest pain and tissue loss, is a highly morbid condition that leads to the loss of ambulation and decreased quality of life. It is associated with a high risk of limb loss and mortality and presents a significant economic burden to society.ImportanceChronic critical limb ischemia, marked by intractable lower extremity ischemic rest pain and tissue loss, is a highly morbid condition that leads to the loss of ambulation and decreased quality of life. It is associated with a high risk of limb loss and mortality and presents a significant economic burden to society.To review the current state of epidemiology, pathophysiology, diagnosis, and treatment of critical limb ischemia.ObjectiveTo review the current state of epidemiology, pathophysiology, diagnosis, and treatment of critical limb ischemia.An extensive literature search of the subject matter was conducted on material published in English between 1980 and 2016; both landmark and recently published articles were evaluated. Articles were reviewed if they included the terms critical limb ischemia, ischemic rest pain, gangrene, or extremity ulcers.Evidence ReviewAn extensive literature search of the subject matter was conducted on material published in English between 1980 and 2016; both landmark and recently published articles were evaluated. Articles were reviewed if they included the terms critical limb ischemia, ischemic rest pain, gangrene, or extremity ulcers.Critical limb ischemia represents the end stage of peripheral arterial disease. Because peripheral arterial disease is most commonly caused by atherosclerosis, critical limb ischemia is heavily associated with smoking and diabetes. Revascularization is the cornerstone of therapy to prevent limb amputation, and both open vascular surgery and endovascular therapy play a key role in the treatment of patients with critical limb ischemia. However, few scientific data are available to identify the optimal revascularization strategy, which has led to a significant amount of variability and equipoise in the treatment of this condition. Medical therapy plays a significant role in optimizing coexistent cardiovascular risk factors and a limited role in improving limb outcomes in nonrevascularizable disease.FindingsCritical limb ischemia represents the end stage of peripheral arterial disease. Because peripheral arterial disease is most commonly caused by atherosclerosis, critical limb ischemia is heavily associated with smoking and diabetes. Revascularization is the cornerstone of therapy to prevent limb amputation, and both open vascular surgery and endovascular therapy play a key role in the treatment of patients with critical limb ischemia. However, few scientific data are available to identify the optimal revascularization strategy, which has led to a significant amount of variability and equipoise in the treatment of this condition. Medical therapy plays a significant role in optimizing coexistent cardiovascular risk factors and a limited role in improving limb outcomes in nonrevascularizable disease.Understanding critical limb ischemia and its treatment strategies is important for providing the best care for affected patients. Currently, ongoing randomized clinical trials in North America and the United Kingdom aim to provide data to support the best management of these patients.Conclusions and RelevanceUnderstanding critical limb ischemia and its treatment strategies is important for providing the best care for affected patients. Currently, ongoing randomized clinical trials in North America and the United Kingdom aim to provide data to support the best management of these patients. |
| Author | Eberhardt, Robert T Farber, Alik |
| Author_xml | – sequence: 1 givenname: Alik surname: Farber fullname: Farber, Alik organization: Department of Surgery, Boston University Medical Center, Boston, Massachusetts – sequence: 2 givenname: Robert T surname: Eberhardt fullname: Eberhardt, Robert T organization: Department of Medicine, Boston University Medical Center, Boston, Massachusetts |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27551978$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNT0tLw0AYXKRia-0f8CB79JK6j-xm68kSfBQKgq3n8GXzxW7JJjWbVPrvrVjBOcwMzDAwl2RQNzUScs3ZlDPG77bgIfTtx1Qwrn_InJGR4NpEWmgx-OeHZBLClh1hGIvl7IIMRaIUnyVmRB7WG6Rp37ZYd3TVQYe0KWnaus5ZqOjS-Zwugt2gd3BP53R1CB16OKb0DfcOv67IeQlVwMlJx-T96XGdvkTL1-dFOl9GIIXooqJQpVKIQqtE51wWFqyWEpTRQlpEw0qdAyYcLINkVsalkNpYHUOChidWjMnt7-6ubT57DF3mXbBYVVBj04eMm5hzaaRSx-rNqdrnHots1zoP7SH7ey2-Ad6PXGw |
| CitedBy_id | crossref_primary_10_3390_diagnostics13193145 crossref_primary_10_1177_1708538120971972 crossref_primary_10_1007_s12265_020_10066_9 crossref_primary_10_1016_j_jvs_2017_01_025 crossref_primary_10_1038_s41598_020_67336_4 crossref_primary_10_1186_s12893_024_02618_6 crossref_primary_10_1007_s11936_023_01001_7 crossref_primary_10_3390_jcm7040082 crossref_primary_10_1136_bmj_m2812 crossref_primary_10_1016_j_biopha_2023_115634 crossref_primary_10_1371_journal_pone_0275628 crossref_primary_10_1016_j_avsurg_2023_100206 crossref_primary_10_3390_jcm10132865 crossref_primary_10_1016_j_jiec_2021_09_020 crossref_primary_10_1136_bmjopen_2020_037879 crossref_primary_10_1016_j_avsg_2020_06_057 crossref_primary_10_1016_j_ajmo_2025_100087 crossref_primary_10_1177_1358863X19878271 crossref_primary_10_1177_17085381211059383 crossref_primary_10_1016_j_jvs_2017_10_076 crossref_primary_10_1097_PRS_0000000000009132 crossref_primary_10_1016_j_ejvs_2020_03_018 crossref_primary_10_1016_j_jvsvi_2024_100141 crossref_primary_10_1016_j_ejvs_2023_07_055 crossref_primary_10_1038_s41569_021_00663_9 crossref_primary_10_1161_ATVBAHA_120_315028 crossref_primary_10_1016_j_actbio_2022_03_021 crossref_primary_10_1016_j_jvs_2018_11_042 crossref_primary_10_1016_j_jvs_2025_04_003 crossref_primary_10_3389_fmed_2022_938634 crossref_primary_10_2337_dc20_0581 crossref_primary_10_1097_SLA_0000000000005058 crossref_primary_10_1016_j_jcmg_2020_09_033 crossref_primary_10_7759_cureus_36192 crossref_primary_10_1177_1708538120905440 crossref_primary_10_1016_j_ijmedinf_2017_12_024 crossref_primary_10_1161_ATVBAHA_120_315151 crossref_primary_10_1161_CIRCIMAGING_118_007726 crossref_primary_10_1186_s12882_019_1662_x crossref_primary_10_1177_2050312119854579 crossref_primary_10_1111_papr_13421 crossref_primary_10_3389_fbioe_2025_1607605 crossref_primary_10_3390_biomedicines11123157 crossref_primary_10_1016_j_avsg_2017_08_033 crossref_primary_10_1080_1061186X_2025_2544786 crossref_primary_10_1007_s11886_024_02027_4 crossref_primary_10_1186_s40780_020_00173_9 crossref_primary_10_1007_s11886_022_01643_2 crossref_primary_10_1177_1538574419885478 crossref_primary_10_1039_C9BM00915A crossref_primary_10_1016_j_avsg_2018_04_007 crossref_primary_10_1016_j_yasu_2018_03_012 crossref_primary_10_1161_CIRCRESAHA_121_320702 crossref_primary_10_1016_j_surg_2017_10_052 crossref_primary_10_1177_1526602818817887 crossref_primary_10_1016_j_avsg_2021_04_024 crossref_primary_10_1016_j_carrev_2021_04_010 crossref_primary_10_1111_dom_15221 crossref_primary_10_1016_j_jvs_2021_03_023 crossref_primary_10_1016_j_jvs_2018_05_255 crossref_primary_10_1002_ccd_29086 crossref_primary_10_1016_j_jvs_2019_10_094 crossref_primary_10_1111_wrr_12975 crossref_primary_10_3390_bioengineering12010092 crossref_primary_10_1007_s00270_017_1670_9 crossref_primary_10_1016_j_jcin_2021_08_079 crossref_primary_10_1002_ccd_27900 crossref_primary_10_3389_fphar_2022_974775 crossref_primary_10_2217_rme_2020_0023 crossref_primary_10_1186_s13036_023_00330_2 crossref_primary_10_1002_sctm_18_0025 crossref_primary_10_1134_S0006350921040096 crossref_primary_10_1016_j_ejim_2024_02_036 crossref_primary_10_1089_jpm_2018_0154 crossref_primary_10_1002_stem_3250 crossref_primary_10_1016_j_avsg_2021_09_030 crossref_primary_10_1002_advs_202003119 crossref_primary_10_1073_pnas_2208541120 crossref_primary_10_1016_j_avsg_2020_11_025 crossref_primary_10_3390_life13020485 crossref_primary_10_1016_j_ijcard_2020_06_016 crossref_primary_10_1038_s41536_021_00159_7 crossref_primary_10_1186_s13287_023_03390_9 crossref_primary_10_3390_jcm12113691 crossref_primary_10_1177_1538574418823378 crossref_primary_10_3390_polym13203568 crossref_primary_10_1159_000529115 crossref_primary_10_1055_s_0041_1736657 crossref_primary_10_1177_1358863X18824654 crossref_primary_10_1111_iwj_13223 crossref_primary_10_3389_fendo_2017_00350 crossref_primary_10_1016_j_jvs_2018_01_067 crossref_primary_10_37699_2308_7005_2_2025_20 crossref_primary_10_1016_j_avsg_2024_09_065 crossref_primary_10_1161_ATVBAHA_120_312862 crossref_primary_10_1002_adma_202110352 crossref_primary_10_1016_j_lfs_2023_121478 crossref_primary_10_3390_gels11070544 crossref_primary_10_3390_biomedicines13040828 crossref_primary_10_1177_17085381221084817 crossref_primary_10_1186_s13287_022_03148_9 crossref_primary_10_1002_adfm_202105475 crossref_primary_10_1016_j_avsg_2022_06_005 crossref_primary_10_3389_fcvm_2022_929466 crossref_primary_10_3233_BMR_220398 crossref_primary_10_3390_life13081783 crossref_primary_10_1053_j_jfas_2021_08_001 crossref_primary_10_3389_fphar_2017_00528 crossref_primary_10_1016_j_jnutbio_2019_04_010 crossref_primary_10_4103_ijri_IJRI_208_19 crossref_primary_10_1016_j_mehy_2021_110548 crossref_primary_10_2147_IJGM_S429768 crossref_primary_10_1016_j_jvs_2024_08_062 crossref_primary_10_1016_j_bioactmat_2023_04_006 crossref_primary_10_1177_0003319720976823 crossref_primary_10_1111_iwj_13232 crossref_primary_10_3389_fcvm_2021_712903 crossref_primary_10_1016_j_cej_2021_131504 crossref_primary_10_1016_j_jvs_2018_04_049 crossref_primary_10_3389_fmolb_2022_929718 crossref_primary_10_1016_j_avsg_2018_02_044 crossref_primary_10_1016_j_avsg_2019_10_042 crossref_primary_10_4103_rcm_rcm_22_19 crossref_primary_10_1056_NEJMoa2207899 crossref_primary_10_1016_j_yasu_2024_04_008 crossref_primary_10_1111_os_14222 crossref_primary_10_1007_s00772_022_00963_5 crossref_primary_10_1007_s00441_021_03562_0 crossref_primary_10_1016_j_biomaterials_2021_120872 crossref_primary_10_1016_j_mehy_2024_111507 crossref_primary_10_1161_CIRCOUTCOMES_120_007539 crossref_primary_10_1111_1753_0407_13527 crossref_primary_10_1007_s00270_019_02223_8 crossref_primary_10_1016_j_ejvs_2018_10_024 crossref_primary_10_1155_2022_3954740 crossref_primary_10_3389_fimmu_2021_774052 crossref_primary_10_1002_term_3109 crossref_primary_10_1016_j_jvn_2020_08_002 crossref_primary_10_1056_NEJMcp1709326 crossref_primary_10_1016_j_tcm_2019_04_002 crossref_primary_10_1016_j_cjca_2022_02_029 crossref_primary_10_1900_RDS_2022_18_20 crossref_primary_10_1007_s11886_018_1019_2 crossref_primary_10_1186_s12951_024_02603_4 crossref_primary_10_1016_j_jvs_2018_03_408 crossref_primary_10_1155_2021_6699292 crossref_primary_10_2147_CIA_S272078 crossref_primary_10_1016_j_avsg_2017_11_072 crossref_primary_10_1016_j_avsg_2023_12_102 crossref_primary_10_1177_1538574421989516 crossref_primary_10_1002_adhm_202001014 crossref_primary_10_1007_s11626_017_0151_4 crossref_primary_10_1097_SLA_0000000000004677 crossref_primary_10_1016_j_jvs_2019_07_103 crossref_primary_10_1177_15385744221086347 crossref_primary_10_1136_bmjopen_2017_016030 crossref_primary_10_1177_1526602819827295 crossref_primary_10_1186_s13287_023_03435_z crossref_primary_10_3389_fphar_2023_1255904 crossref_primary_10_1016_j_avsg_2023_12_100 crossref_primary_10_1016_j_avsg_2018_10_045 crossref_primary_10_1016_j_cpm_2025_06_012 crossref_primary_10_1016_j_ymthe_2019_10_017 crossref_primary_10_1016_j_jconrel_2020_03_017 crossref_primary_10_1111_wrr_13081 crossref_primary_10_1177_15266028231219659 crossref_primary_10_1007_s00270_019_02253_2 crossref_primary_10_1016_j_jvs_2021_04_026 crossref_primary_10_1111_jocn_16871 crossref_primary_10_1177_09612033231177788 crossref_primary_10_1016_j_orthop_2022_07_002 crossref_primary_10_1016_j_bjps_2022_04_080 crossref_primary_10_1016_j_ejvs_2020_04_027 crossref_primary_10_1007_s00398_019_0310_x crossref_primary_10_1016_j_ejvs_2021_10_037 crossref_primary_10_1002_adfm_202416553 crossref_primary_10_1016_j_mri_2022_01_001 crossref_primary_10_1016_j_avsg_2021_10_041 crossref_primary_10_1016_j_yjmcc_2020_08_004 crossref_primary_10_1080_09638288_2023_2291552 crossref_primary_10_1016_j_avsg_2022_03_035 crossref_primary_10_23736_S0021_9509_21_11654_4 crossref_primary_10_3390_ijerph191912818 crossref_primary_10_1016_j_ejvs_2020_02_032 crossref_primary_10_1177_02841851221102788 crossref_primary_10_1186_s40001_018_0324_y |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1001/jamasurg.2016.2018 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2168-6262 |
| ExternalDocumentID | 27551978 |
| Genre | Systematic Review Journal Article |
| GroupedDBID | 0R~ 4.4 AAWTL ABBLC ABJNI ACDNT ACGFS ADBBV AENEX AHMBA ALMA_UNASSIGNED_HOLDINGS AMJDE ANMPU BRYMA C45 CGR CUY CVF EBD EBS ECM EIF EJD EMOBN EX3 GX1 H13 NPM OB2 OBH OHH OVD PQQKQ RAJ SV3 TEORI WOW 7X8 |
| ID | FETCH-LOGICAL-a322t-dd5f55ee26576b13dcac633a58623cee80f6bae71ac0a79f4f2368c64a7e817c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 224 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000388404500022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2168-6262 |
| IngestDate | Sun Nov 09 09:09:30 EST 2025 Sat Jun 28 01:34:50 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a322t-dd5f55ee26576b13dcac633a58623cee80f6bae71ac0a79f4f2368c64a7e817c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| PMID | 27551978 |
| PQID | 1841138355 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1841138355 pubmed_primary_27551978 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-11-01 |
| PublicationDateYYYYMMDD | 2016-11-01 |
| PublicationDate_xml | – month: 11 year: 2016 text: 2016-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JAMA surgery |
| PublicationTitleAlternate | JAMA Surg |
| PublicationYear | 2016 |
| SSID | ssj0000800439 |
| Score | 2.5998015 |
| SecondaryResourceType | review_article |
| Snippet | Chronic critical limb ischemia, marked by intractable lower extremity ischemic rest pain and tissue loss, is a highly morbid condition that leads to the loss... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1070 |
| SubjectTerms | Amputation, Surgical Chronic Disease Diabetes Complications - complications Diabetes Mellitus - drug therapy Humans Hyperbaric Oxygenation Hyperlipidemias - drug therapy Hypertension - drug therapy Ischemia - diagnosis Ischemia - epidemiology Ischemia - etiology Ischemia - therapy Lower Extremity - blood supply Peripheral Arterial Disease - complications Peripheral Arterial Disease - surgery Platelet Aggregation Inhibitors - therapeutic use Smoking - adverse effects Smoking Cessation Upper Extremity - blood supply |
| Title | The Current State of Critical Limb Ischemia: A Systematic Review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27551978 https://www.proquest.com/docview/1841138355 |
| Volume | 151 |
| WOSCitedRecordID | wos000388404500022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSwMxFA5qPXhxwa1uRPAabPaMFy1iUdBSUKG3IZkk0kNnaqf195vMUk-C4GVugeHl5b3veysAVzyOAA-OEVmTWMQSx5C2gbVqJq2RxFnKTLVsQg6HajxORk3ArWzKKlubWBlqW2QxRn4dmAjGgU5xfjv7RHFrVMyuNis01kGHBigTtVqO1SrGEtEQq5aJESwUCtidNH0z7eChcjn_iPVdsVgBq99RZuVtBjv__c9dsN3gTNivFWMPrLl8H9wFpYDNRCZYwUxYeNhuO4DPk6mBT4HuuulE38A-fF2NeYZ1DuEAvA8e3u4fUbNCAenwUhfIWu45d46IwCsMpjbTmaBU80BkaPCPqueF0U5infW0TDzzhAqVCaalU1hm5BBs5EXujmMNlDE9S7SzVjDhjcaaaeISr32wVJ52wWUrkDSoaMw76NwVyzL9EUkXHNVSTWf1LI2USB5bZ9XJH06fgq14VXUn4Bno-PBA3TnYzL4Wk3J-Ud19-A5HL98SaLkN |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Current+State+of+Critical+Limb+Ischemia%3A+A+Systematic+Review&rft.jtitle=JAMA+surgery&rft.au=Farber%2C+Alik&rft.au=Eberhardt%2C+Robert+T&rft.date=2016-11-01&rft.eissn=2168-6262&rft.volume=151&rft.issue=11&rft.spage=1070&rft_id=info:doi/10.1001%2Fjamasurg.2016.2018&rft_id=info%3Apmid%2F27551978&rft_id=info%3Apmid%2F27551978&rft.externalDocID=27551978 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2168-6262&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2168-6262&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2168-6262&client=summon |